LUNG CANCER

Datopotamab deruxtecan for the treatment of advanced non–small cell lung cancer is ongoing investigation in multiple clinical trials.

In patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.

According to Shirish M. Gadgeel, MD, adagrasib demonstrated durable clinical benefit [and] there were no new safety signals.

As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.

Alectinib is the first and only ALK inhibitor to demonstrate a reduction in disease recurrence among patients with early-stage ALK-positive non–small cell lung cancer, based on data from the phase 3 ALINA study.

During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.

A retrospective study found no additional benefit for patients with non–small cell lung cancer who continued immunotherapy beyond 2 years.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed the importance of patient characteristics and biomarkers in choosing an immunotherapy-containing regimen for patients with non–small cell lung cancer, particularly if their PD-L1 expression is low. This is the first of 2 articles based on this event.

Frontline treatment with AK112, a first-in-class humanized IgG1 bispecific antibody, plus chemotherapy demonstrated promising overall responses across 3 cohorts in a phase 2 trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed biopsy and treatment approaches for a patient diagnosed with T2aN2M0, stage IIIA adenocarcinoma.

In an interview with Targeted Oncology, Se-Hoon Lee, MD, highlights the results of the long-term analysis of the CHRYSALIS trial looking at amivantamab and lazertinib for patients with EGFR mutated non–small cell lung cancer.

Findings from a study published in JAMA Oncology showed no survival difference in fixed duration immune checkpoint inhibitor group vs the indefinite-duration group among patients with non–small cell lung cancer

Approval of pralsetinib for the treatment of RET fusion-positive non–small cell lung cancer in based on positive results from the phase 1/2 ARROW trial.

A positive association with progression-free survival in patients with advanced non–small cell lung cancer who were treated with first-line pembrolizumab was observed using a multiomics approach.

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

In an interview with Targeted Oncology™, Patricia Rich, MD, discussed the data presented at ASCO 2023 and other recent trials that she found most exciting and important to the field of NSCLC treatment.

Hatim Husain, MD, discussed with participants the case of a patient with lung adenocarcinoma.

In the second part of a 2-part article series, Kartik Konduri, MD, discusses the outcomes of targeting the KRAS G12C mutation in patients with metastatic NSCLC.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed with participants what therapy to use, including adjuvant immunotherapy, for a patient with stage III non–small cell lung cancer. This is the second of 2 articles based on this event.

During a Targeted Oncology™ Clinical Case Forum™ event, Ronan J. Kelly, MD, MBA, discussed the significance of the CheckMate 9LA, KEYNOTE-407, EMPOWER-Lung 3, and POSEIDON studies which all explored immunotherapies in patients with advanced non–small cell lung cancer.

Without requiring additional therapy, 2 patients with non–small cell lung cancer treated with THIO and cemiplimab remained free of disease progression in the phase 2 THIO-101 study.

In the first of a 2-part article series, Kartik Konduri, MD, discusses the data behind the use of adagrasib and sotorasib for patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed options including concurrent chemoradiation therapy and neoadjuvant therapy for a patient with stage IIIA lung adenocarcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Christopher G. Azzoli, MD, discussed treatment options appropriate for a patient who received surgical resection for stage IIB lung adenocarcinoma.

Data from a phase 1 dose escalation study showed tolerability and antitumor activity with IBI351 in patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed practice management strategies as a thoracic medical oncologist, including multidisciplinary care, communication between inpatient and outpatient oncology services, and advice on end-of-life care.

The phase 3 LUNAR trial evaluating tumor treating fields with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer.

Phase 2 results have placed a novel EGFR exon 20 insertion inhibitors in the realm of possibilities for future treatment of previously-treated non–small cell lung cancer with EGFR exon 20 insertions in the tumor tissue.

New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.